Short answer
ASP Isotopes Inc. (ASPI) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Shareholder letter issued August 4, 2026, providing investors with management’s current company update.
ASP Isotopes Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Shareholder letter issued August 4, 2026, providing investors with management’s current company update
- Exhibit 99.1 contains the substantive disclosure and should be reviewed for operating developments and outlook
Item 7.01 · Regulation FD Disclosure
- Item 7.01 incorporates the Item 2.02 earnings disclosure by reference
- Investor-relevant information is contained in the Item 2.02 exhibit rather than this section
Item EX-99.1 · Exhibit EX-99.1
- PET Labs 1H 2026 organic revenue growth exceeded 50%; FY 2026 revenue forecast approximately $14 million versus $6 million in 2025
- Renergen helium production targeted before September 30, 2026, with Phase 1 annualized revenue forecast above $27 million
- Phase 2 expected to receive approximately $750 million senior debt funding, subject to definitive agreements
- Noble Africa reverse merger could create Nasdaq-listed helium company; ASPI expected to retain approximately 89% ownership
- Management reiterates 2031 EBITDA target above $300 million, but projections remain subject to execution and unavailable GAAP reconciliation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ASP Isotopes Inc. 8-K filings
Get the next ASPI 8-K as it lands
Follow ASPI for push alerts, or ask the research agent what this filing means.